ArticleJACC. Case reports2026
Heyde Syndrome in Moderate Bioprosthetic Aortic Valve Stenosis: A Twist in the Valve.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeyde syndrome (HS) is a rare disease characterized by aortic stenosis (AS), gastrointestinal bleeding, and acquired von Willebrand syndrome. CASE SUMMARY: A 91-year-old woman with anemia and (recurrent) AS with subsequent surgical bioprosthetic aortic valve replacement presented with exertional chest tightness. Work-up revealed marked anemia with hemoglobin of 6.8 g/dL, a degenerative bioprosthetic aortic valve with moderate AS, multiple bleeding cecal angiodysplastic lesions, and platelet dysfunction, supporting a diagnosis of HS. Aortic valve replacement was deferred. Conservative treatment included endoscopic ablation of angiodysplasias, blood transfusions, and iron supplementation. DISCUSSION: Existing guidelines recommend aortic valve replacement for symptomatic severe AS, but no specific recommendations for moderate bioprosthetic valve AS with HS exist. This creates a clinical gap with individualized treatment. TAKE-HOME MESSAGE: HS is under-recognized; treatment of HS in the context of moderate bioprosthetic valve AS falls outside evidence-based pathways and may be managed by conservative strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.